What stands out
- Wegovy pill and injectable choices
- Ongoing care through a membership
What to weigh
- Paying a membership fee does not guarantee a prescription.
- Provider performance is not established by branded-drug trial results.
Different medication formats under one care service
The current Hers menu includes Wegovy pill and Zepbound KwikPen, among other treatments. These are materially different formats: a daily oral semaglutide product and a weekly injectable tirzepatide presentation.[source]
The platform should not be summarized using older assumptions that every offer is a compounded injection. Our selected reviews follow the current named products and distinguish them from the surrounding care membership.
The medicine price is not the total
Hers advertises a $39 initial membership month followed by automatic renewal at $149 per month. Its medication prices are additional. An active membership is required, and the membership itself does not guarantee a prescription.[source]
A headline starting price for a medicine therefore understates the complete recurring cost if shown alone. Confirm the selected dose, supply and any eligibility restrictions before calculating the total.
Cancellation also affects medication access
The reviewed product pages explain that canceling membership also cancels an active medication plan and care access through the platform. That is more consequential than ending a standalone content subscription.[source]
Discuss a continuity plan with the clinician if changing services. The review does not advise stopping, restarting or switching medication in response to a billing decision.
Do not force the pill into an injection trial
SURMOUNT-5 studied weekly injections, not the current Wegovy tablet. Its comparison cannot establish how the oral product performs against Zepbound in a head-to-head study.[source]
The Wegovy and Zepbound prescribing information also contain formulation-specific instructions and warnings. The clinician should consider the practical format as well as efficacy evidence.[source][source]
A service to evaluate with both charges visible
Hers may be relevant for readers seeking its online support model and current branded medication menu. Availability and the clinically appropriate prescription remain individual questions. We did not test enrollment, support response or treatment outcomes.
Read the Wegovy pill and Zepbound KwikPen reviews for the product-level distinctions before comparing the membership with another provider.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- Hers: weight-loss membershipMembership fee and medicine costs are separate · Checked October 8, 2026
- Hers: Wegovy pillCurrent product page and starting medication quote · Checked October 8, 2026
- Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026
- Wegovy prescribing informationManufacturer labeling; formulation-specific directions and safety information · Checked October 8, 2026
- Zepbound prescribing informationManufacturer prescribing information, warnings and approved uses · Checked October 8, 2026